Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
复制标题
DOI：
10.3233/jad-2009-1177
复制
发表时间：
2009-01-01
影响因子：
4
通讯作者：
Zetterberg, Henrik
中科院分区：
文献类型：
--
作者：
Blennow, Kaj;Zetterberg, Henrik
研究进展使人们对阿尔茨海默病（AD）的分子发病机制有了详细的了解，这已经转化为疾病改善治疗的持续发展。这些新的候选药物的目标是抑制淀粉样蛋白（A β）的产生和聚集或tau聚集。如果这些药物被证明是有效的，那么早期诊断阿尔茨海默病的诊断工具将具有很大的价值。此外，在药物开发中，重要的是共同开发生物标志物，作为直接识别和监测药物在患者体内的生化效应的工具。阿尔茨海默病脑中的分子畸变反映在脑脊液（CSF）中。核心候选脑脊液生物标志物A β(42)、总tau （T-tau）和磷酸化tau （P-tau）已被证明在阿尔茨海默病的早期阶段也具有很高的诊断性能。本文综述了近年来脑脊液生物标志物在阿尔茨海默病临床诊断和临床试验中的研究进展。
Research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an ongoing development of disease-modifying treatments. These new drug candidates are targeted on inhibiting amyloid-beta (A beta) production and aggregation or tau aggregation. If these drugs prove to be efficient, diagnostic tools enabling early diagnosis of AD will be of great value. Also in drug development, it is important to co-develop biomarkers to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). The core candidate CSF biomarkers A beta(42), total tau (T-tau), and phosphorylated tau (P-tau) have been shown to have a high diagnostic performance to identify AD also in the early phase of the disease. This paper reviews recent research advances on these CSF biomarkers for use in clinical diagnosis and in clinical trials in AD.